Log in
NASDAQ:HARP

Harpoon Therapeutics Stock Forecast, Price & News

$15.34
+0.32 (+2.13 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$14.83
Now: $15.34
$15.71
50-Day Range
$13.61
MA: $16.04
$18.52
52-Week Range
$10.27
Now: $15.34
$25.02
Volume48,175 shs
Average Volume200,586 shs
Market Capitalization$385.68 million
P/E RatioN/A
Dividend YieldN/A
Beta0.89
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.09 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HARP
CUSIPN/A
CIKN/A
Phone650-443-7400
Employees76

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.78 million
Book Value$3.82 per share

Profitability

Net Income$-55,570,000.00
Net Margins-571.20%

Miscellaneous

Market Cap$385.68 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$15.34
+0.32 (+2.13 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

How has Harpoon Therapeutics' stock price been impacted by COVID-19?

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HARP stock has increased by 17.4% and is now trading at $15.34.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Harpoon Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Harpoon Therapeutics
.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Harpoon Therapeutics
.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) issued its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.47) by $0.04. The firm earned $2.76 million during the quarter, compared to analysts' expectations of $5.88 million. Harpoon Therapeutics had a negative net margin of 571.20% and a negative return on equity of 62.20%.
View Harpoon Therapeutics' earnings history
.

What price target have analysts set for HARP?

7 equities research analysts have issued 12 month price objectives for Harpoon Therapeutics' shares. Their forecasts range from $25.00 to $38.00. On average, they expect Harpoon Therapeutics' stock price to reach $31.14 in the next twelve months. This suggests a possible upside of 103.0% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics
.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 826,600 shares, an increase of 27.3% from the August 31st total of 649,200 shares. Based on an average daily volume of 340,000 shares, the days-to-cover ratio is presently 2.4 days. Currently, 5.6% of the shares of the company are short sold.
View Harpoon Therapeutics' Short Interest
.

Who are some of Harpoon Therapeutics' key competitors?

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the following people:
  • Dr. Gerald McMahon, Pres, CEO & Director (Age 65, Pay $749.11k)
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 53, Pay $500.79k)
  • Dr. Natalie R. Sacks, Chief Medical Offer (Age 55, Pay $538.42k)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 52)
  • Ms. Rachael Lester, VP of Corp. Devel.
  • Dr. Susan Dana Jones Ph.D., Sr. VP of Product Devel.
  • Dr. Che-Leung Law Ph.D., Sr. VP of Translational Medicine
  • Mr. Christopher Whitmore, VP of Fin. & Sec.

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.05%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Luke Evnin, Mark Chin, Natalie Sacks and Patrick Baeuerle.
View institutional ownership trends for Harpoon Therapeutics
.

Which major investors are buying Harpoon Therapeutics stock?

HARP stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, and Luke Evnin.
View insider buying and selling activity for Harpoon Therapeutics
.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $15.34.

How big of a company is Harpoon Therapeutics?

Harpoon Therapeutics has a market capitalization of $385.68 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Harpoon Therapeutics employs 76 workers across the globe.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is www.harpoontx.com.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.